Literature DB >> 23336960

Reduction and the intracellular translocation of EphB2 in Tg2576 mice and the effects of β-amyloid.

M Qu1, J Jiang, X-P Liu, Q Tian, L-M Chen, G Yin, D Liu, J-Z Wang, L-Q Zhu.   

Abstract

AIMS: EphB2 is a member of receptor tyrosine kinases (RTKs) family that is essential for the cell adhesion, neural crest migration, axon guidance and synaptogenesis in the nervous system. Recent studies show that preservation of EphB2 in a transgenic mouse model of Alzheimer's disease (AD) rescues the cognitive deficit, suggesting a crucial role of EphB2 in AD. However, the expression and distribution profiles of EphB2 in the early stage of AD have not been reported.
METHODS: Immunohistochemistry, immunoblot and immunofluorescence were used to analyse the level of EphB2 in Tg2576 mice at different ages and in cultured neurones with Aβ treatment at different times.
RESULTS: EphB2 was reduced in an age-dependent manner in the olfactory bulb and the hippocampus of Tg2576 mice. The decrease of EphB2 appeared earlier in the olfactory bulb than the hippocampus, and reduction of EphB2 appeared earlier than that of MAP2, a dendritic cytoskeleton marker. In the cortex, EphB2 displayed a significant translocation from the neuronal processes to the cell bodies with ageing. In primary hippocampal neuronal cultures, Aβ42 treatment also induced the decrement of EphB2 that was prior to the decline of MAP2.
CONCLUSIONS: Our findings provide the first evidence for an age- and region-dependent reduction and intracellular translocation of EphB2 in Tg2576 mice, and the foremost decrement of EphB2 in the olfactory bulb may represent an early sign of AD.
© 2013 British Neuropathological Society.

Entities:  

Keywords:  Alzheimer's disease; EphB2; MAP2; hippocampus; olfactory bulb

Mesh:

Substances:

Year:  2013        PMID: 23336960     DOI: 10.1111/nan.12019

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  6 in total

1.  Epigenetic Control of the Notch and Eph Signaling Pathways by the Prion Protein: Implications for Prion Diseases.

Authors:  Théo Z Hirsch; Séverine Martin-Lannerée; Fabienne Reine; Julia Hernandez-Rapp; Laetitia Herzog; Michel Dron; Nicolas Privat; Bruno Passet; Sophie Halliez; Ana Villa-Diaz; Caroline Lacroux; Victor Klein; Stéphane Haïk; Olivier Andréoletti; Juan-Maria Torres; Jean-Luc Vilotte; Vincent Béringue; Sophie Mouillet-Richard
Journal:  Mol Neurobiol       Date:  2018-07-11       Impact factor: 5.590

2.  Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β.

Authors:  Jun Jiang; Zhi-Hao Wang; Min Qu; Di Gao; Xiu-Ping Liu; Ling-Qiang Zhu; Jian-Zhi Wang
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

Review 3.  The Role of Ephs and Ephrins in Memory Formation.

Authors:  Monica Dines; Raphael Lamprecht
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

4.  Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2.

Authors:  Koichiro Suzuki; Takahiro Aimi; Tomoaki Ishihara; Tohru Mizushima
Journal:  FEBS Open Bio       Date:  2016-04-01       Impact factor: 2.693

5.  A novel mechanism of synaptic and cognitive impairments mediated via microRNA-30b in Alzheimer's disease.

Authors:  Yunping Song; Mei Hu; Jian Zhang; Zhao-Qian Teng; Chu Chen
Journal:  EBioMedicine       Date:  2018-12-03       Impact factor: 8.143

6.  Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET.

Authors:  Oliver Goldhardt; Inanna Warnhoff; Igor Yakushev; Ilijana Begcevic; Hans Förstl; Viktor Magdolen; Antoninus Soosaipillai; Eleftherios Diamandis; Panagiotis Alexopoulos; Timo Grimmer
Journal:  Transl Neurodegener       Date:  2019-08-27       Impact factor: 8.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.